MRCP Part 1 Rheumatology: Key Concepts & Exam Practice

The key distinction is swelling: inflammatory diseases (rheumatoid arthritis) cause constant joint swelling, while non-inflammatory diseases (osteoarthritis) cause pain primarily with movement. Rheumatoid arthritis is autoimmune, attacking joint walls and cartilage, causing morning stiffness lasting over an hour. Osteoarthritis is degenerative, caused by wear and tear of articular cartilage, affecting weight-bearing joints and joints used repeatedly.

This section covers the fundamental differences between degenerative and inflammatory joint pathology. A joint consists of bones, cartilage, tendons, muscles, and synovial fluid. Degenerative joints show cartilage destruction with particles, loss of joint space, and osteophyte formation. Inflammatory joints exhibit cartilage destruction, joint space narrowing, synovitis, and effusion (excess synovial fluid causing swelling). Key rheumatology terminology includes arthritis (joint inflammation), arthralgia (joint pain), and arthroscopy (surgical examination). Inflammatory joints are associated with elevated ESR and CRP markers.

This section covers the fundamental anatomy of joints including bones, cartilage, tendons, muscles, and synovial fluid. It explains how to differentiate degenerative joints (characterized by cartilage destruction, cartilage particles, loss of joint space, and osteophyte formation) from inflammatory joints (characterized by cartilage destruction, joint space narrowing, synovitis, effusion, and elevated inflammatory markers like ESR and CRP). Key terminology includes arthritis (inflammation of joints) and arthralgia (joint pain).

Joint disease can be differentiated as inflammatory or non-inflammatory. Non-inflammatory joint disease has no synovial membrane inflammation, no systemic signs and symptoms, and normal synovial fluid analysis. Inflammatory joint disease is more systemic with systemic signs and symptoms. This differentiation is important for appropriate treatment approaches.

Arthritis is an inflammatory joint condition characterized by redness, swelling, severe pain, and elevated temperature, typically occurring after trauma or as part of autoimmune diseases. Osteoarthritis is a degenerative-dystrophic process representing joint aging due to poor blood circulation. The term literally means 'condition of the joint.' Specific types include coxarthrosis (hip), gonarthrosis (knee), and polyarthritis (small joints). When bone damage occurs, it becomes osteoarthritis; with deformity, it becomes deforming osteoarthritis.

This lecture covers three major anti-inflammatory drug classes: corticosteroids (glucocorticoids like hydrocortisone, prednisone, dexamethasone, and betamethasone) which decrease prostaglandins and have immunosuppressive effects but cause side effects like osteoporosis, hypertension, and adrenal suppression requiring gradual tapering; NSAIDs (ibuprofen, naproxen, celecoxib) which inhibit COX enzymes to reduce inflammation but carry risks of GI bleeding, nephrotoxicity, and cardiovascular events; and DMARDs (methotrexate, hydroxychloroquine, biologics like adalimumab) which modify disease progression in autoimmune conditions like rheumatoid arthritis and lupus but require monitoring for infections and organ toxicity.

Methotrexate is the first-line DMARD for moderate-severe RA, inhibiting aminoimidazolecarboxamide ribonucleotide transformylase to suppress T cell activation and cytokine production. Azathioprine, a prodrug metabolized to 6-thioguanine, inhibits T/NK cell differentiation as a steroid-sparing agent. Hydroxychloroquine induces lysosomal stabilization to prevent antigen processing and T cell activation. Sulfasalazine splits into 5-aminosalicylic acid (colonic anti-inflammatory) and sulfapyridine (systemic suppression of oxidative stress and cytokines). Leflunomide inhibits dihydroorotate dehydrogenase to block pyrimidine synthesis in activated T cells. All conventional DMARDs require careful monitoring due to significant adverse effect profiles including bone marrow suppression, hepatotoxicity, and teratogenicity.

Rheumatoid arthritis treatment involves three main drug classes: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for acute pain relief without affecting disease progression; Corticosteroids serving as bridge therapy until Disease-Modifying Antirheumatic Drugs (DMARDs) take effect, and as adjunctive therapy for persistent active disease; and DMARDs divided into synthetic agents (methotrexate, sulfasalazine, leflunomide, hydroxychloroquine, minocycline, tofacitinib, gold salts, penicillamine) and biological agents (TNF-alpha inhibitors like etanercept, infliximab, adalimumab; co-stimulatory inhibitors like abatacept; IL-6 inhibitors like tocilizumab; and B-cell depleting agents like rituximab).

This section covers the pharmacological management of rheumatoid arthritis. NSAIDs provide symptomatic relief but do not alter disease progression. Corticosteroids provide potent anti-inflammatory effects but require careful monitoring for side effects. Conventional DMARDs include methotrexate (first-line), hydroxychloroquine, and sulfasalazine. Methotrexate requires monitoring for bone marrow suppression, hepatotoxicity, and lung toxicity. Hydroxychloroquine is safer in pregnancy and for patients with tuberculosis. These drugs work broadly on the immune system but lack the precision of biologic agents.

RA pharmacological treatment aims to minimize pain, swelling, prevent bone destruction, and reduce disability. NSAIDs (ibuprofen, naproxen, aspirin) relieve pain and inflammation but carry high GI side effect risks (ulcers, bleeding) and may accelerate cartilage erosion long-term. COX-2 inhibitors (celecoxib) are easier on the stomach but carry higher heart attack/stroke risk (Vioxx removed 2004, Bextra 2005). Corticosteroids (prednisone, prednisolone) are powerful anti-inflammatories suppressing immunity, used as bridge therapy (7.5mg daily) or for acute flares (25mg daily). Side effects include edema, weight gain, hypertension, glaucoma, mood changes, infection risk, and osteoporosis. DMARDs (disease-modifying anti-rheumatic drugs) are the mainstay, working slowly to modify disease course and prevent joint destruction. Methotrexate (7.5-25mg weekly) is most common, taking 3-12 weeks to work, with 15% liver enzyme elevation risk and teratogenicity. If symptoms persist after 12 weeks, biologic agents are considered.

Inflammatory markers guide assessment of disease activity. ESR measures red blood cell settling rate - faster settling indicates more inflammation. CRP is a liver-produced protein more specific for acute inflammation. Both are used together: ESR is less specific (affected by age, blood proteins, thyroid disorders), while CRP is more specific. Urinalysis evaluates protein (hypertension/kidney disease, monitored in lupus), specific gravity (hydration status), bacteria/nitrites/white cells (UTI indicators requiring culture), glucose (diabetes or steroid-induced), and blood (bleeding disorders, stones, infections). Synovial fluid analysis from joint aspiration detects white blood cells (inflammation/infection), red blood cells (bleeding/trauma), and crystals (monosodium urate = gout, calcium pyrophosphate = pseudogout).

Essential RA tests include CBC, ESR, CRP, RF, and anti-CCP antibodies, available across all healthcare settings. Acute phase reactants (CRP, fibrinogen, alpha-1 protease inhibitor) show varying elevations during inflammation. Inflammatory synovial fluid is identified via aspiration showing elevated WBC (>2000/μL), low glucose, and neutrophils. When ordering investigations, clinicians must consider patient affordability and start with basic tests before advanced imaging. CT/MRI should be reserved for suspected complications or when basic investigations are inconclusive.

ESR measures red blood cell settling rate over one hour, reflecting plasma viscosity changes due to acute phase proteins. Normal values: men = age/2, women = (age+10)/2. CRP rises rapidly during bacterial infections and moderately during viral infections, helping immune recognition of damaged cells and tumors. CRP >10 mg/L indicates significant active inflammation; 3-10 mg/L suggests low-grade inflammation. Both tests are nonspecific but valuable for tracking disease activity in inflammatory and autoimmune conditions.

Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are acute phase reactants that increase during inflammation but lack diagnostic specificity; ESR measures the rate at which red blood cells settle in a tube (reported in mm/hour, with normal values <15 mm/hour for males under 50 and <20 mm/hour for females under 50), while CRP is a liver-produced protein synthesized in response to interleukin-6 from inflammatory cells; both correlate with disease activity and treatment response in conditions like rheumatoid arthritis, but neither can definitively diagnose a specific condition due to their high sensitivity and low specificity across numerous inflammatory and non-inflammatory conditions.

This lecture provides a comprehensive framework for interpreting acute phase reactants in clinical practice. Inflammation, derived from 'flamma,' has evolved from Celsus's classical signs to modern understanding including low-grade inflammation associated with metabolic syndrome. Acute phase reactants are liver-produced proteins changing by 25%+ during inflammation, primarily driven by IL-6. Key markers include CRP (fast response, 4-7 hour half-life) and ESR (slower, affected by multiple factors). IL-6 blockers suppress these markers, potentially masking infections and disease activity. Alpha-1 acid glycoprotein, the most intense reactant, can lead to amyloidosis in chronic inflammation. ESR measures red blood cell sedimentation, influenced by sialic acid coating. Positive-charged proteins cause rouleaux formation. Inflammatory ESR elevation shows proportional CRP elevation with patients appearing clinically ill. Non-inflammatory ESR elevation (monoclonal gammopathies) shows elevated ESR with normal CRP and surprisingly well-appearing patients. ESR >100 mm/hour requires clear diagnosis (90% of cases): infections, autoimmune diseases, malignancies, or renal disease. CRP is a pentraxin promoting phagocytosis, with half-life 4-7 hours. Mild elevation occurs with obesity and minor infections; markedly elevated CRP (>10 mg/dL) indicates bacterial infection or severe inflammation. Lupus typically shows elevated ESR but normal CRP due to interferon signature suppressing IL-6. Clinical case studies demonstrate how these markers distinguish between conditions: ESR >100 with normal CRP suggests multiple myeloma; polymyalgia-like symptoms with elevated CRP and jaw claudication indicate giant cell arteritis; lupus with elevated ESR but normal CRP versus rheumatoid arthritis with elevated CRP.